Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Bayer Japan Chief “Disappointed” at PMP Removal for Xarelto, Shows Eagerness for Add’l Indications
April 27, 2018
-
REGULATORY Imfinzi Sails through MHLW Panel, Now in Line for Stage III NSCLC Nod
April 26, 2018
-
ORGANIZATION PhRMA/EFPIA Say Humira, Jevtana, Xarelto Lost Eligibility under New PMP, Innovation Not Appropriately Defined
April 26, 2018
-
BUSINESS Takeda, Shire Reach Preliminary Deal, Extend Takeover Deadline to May 8
April 25, 2018
-
BUSINESS Takeda Makes Fifth Pitch for Shire Buyout as Deadline Looms
April 25, 2018
-
BUSINESS Novartis Seeks Japan Approval for Kymriah, Will Outcome-Based Model Be Put in Place?
April 24, 2018
-
ACADEMIA Clinical Trials for Mitochondrial Disease Heating Up with AMED’s Support; Filing for First Hyperlactacidemia Drug Expected in 2020
April 23, 2018
-
BUSINESS Takeda Sweetens Bid for Shire, Ups Cash Component
April 23, 2018
-
BUSINESS Takeda in Talks with Shire after 3 Buyout Proposals Rejected
April 20, 2018
-
TRENDS Industry Group Anticipates New Demand for Contract Reps after Current Phase of Downsizing by Drug Makers
April 20, 2018
-
BUSINESS Tecentriq Now in PD-1/L1 NSCLC Showdown, Lynparza Also Hits Japan Market
April 19, 2018
-
ACADEMIA Physicians Association Initiates Large-Scale Study to Directly Compare DPP-4 Inhibitors to SGLT2 Inhibitors, Determine “Optimal Patients” for Each
April 19, 2018
-
BUSINESS Another Huge Seller Re-Pricing Won’t Hit Opdivo Unless 195 Billion Yen Sales Reached: Ono Chief
April 18, 2018
-
BUSINESS Sumitomo Dainippon Reorganizes Drug Discovery Research System; Accelerating Decision-Making: Pres.
April 18, 2018
-
REGULATORY Pharma Leaders Air Grievances on Pricing Reform Package at New MHLW Confab
April 17, 2018
-
BUSINESS Takeda CEO Eager to Lure More Partners to Shonan iPark, Says Diversity Is Source of Creativity
April 16, 2018
-
BUSINESS Shonan Health Innovation Park Marks Grand Opening: Takeda
April 16, 2018
-
ORGANIZATION PhRMA Chief Warns of Serious Implications for Japan Market after 2018 Pricing Reform
April 13, 2018
-
REGULATORY Chuikyo Payer Rep Questions New Premium System for Cost-Based Pricing Method
April 12, 2018
-
REGULATORY MOF Calls for Using CEA to Make Reimbursement Decisions for Pricy Drugs
April 12, 2018
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…